Recombinant human parathyroid hormone
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Recombinant human parathyroid hormone?
Summarize this article for a 10 year old
Recombinant human parathyroid hormone, sold under the brand name Preotact among others, is an artificially manufactured form of the parathyroid hormone used to treat hypoparathyroidism (under-active parathyroid glands).[1][2][4][5] Recombinant human parathyroid hormone is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures.[3] A significant reduction in the incidence of vertebral fractures has been demonstrated.[3] It is used in combination with calcium and vitamin D supplements.[1][4]
Clinical data | |
---|---|
Trade names | Preotact, Natpara, Natpar |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617013 |
License data | |
Routes of administration | Subcutaneous |
Drug class | Hormonal agent |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C408H674N126O126S2 |
Molar mass | 9424.76 g·mol−1 |
The most common side effects include sensations of tingling, tickling, pricking, or burning of the skin (paraesthesia); low blood calcium; headache; high blood calcium; and nausea.[2]
Recombinant human parathyroid hormone (Preotact) was approved for medical use in the European Union in April 2006.[3] Recombinant human parathyroid hormone (Natpara) was approved for medical use in the United States in January 2015, and in the European Union (as Natpar) in February 2017.[4][6]